# US 2013/0157884 A1 · Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157884 A1
- Document ID: US20130157884A1
- Status: Published application
- Kind: A1
- Application number: 13/662,212
- Filed: 2012-10-26
- Published: 2013-06-20
- Earliest claimed: 2011-10-26
- Assignees: Asuragen, Inc.
- Inventors: Alex T. Adai; Anna E. Szafranska-Schwarzbach; Bemard F. Andruss; Anirban Maitra; Hanno Matthaei; Dennis Wylie; Ralph Hruban
- Web page: https://patentgrep.com/patent/US20130157884A1

## CPC

- C12Q 1/6837: using probe arrays or probe chips (C12Q1/6874 takes precedence)
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G16H 50/30: for calculating health indices; for individual health risk assessment
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Embodiments concern methods and compositions for evaluating a pancreatic cyst in a patient based on the expression levels of one or more miRNAs to determine whether the pancreatic cyst is a low or high risk lesion and in further need of treatment such as resection.

## Claims

### Claim 1

A method for evaluating a pancreatic cyst in a patient comprising:
a) measuring from a pancreatic cyst sample from the patient the level of expression of at least two of the following biomarker miRNAs: miR-24, miR-30a-3p, miR-92a, miR-18a, miR-342-3p, miR-99b, miR-106b, miR-142-3p, or miR-532-3;
b) comparing the level of expression each biomarker miRNA to the level of expression of another biomarker miRNA;
c) calculating a diagnostic score that indicates the probability the pancreatic cyst is a low risk or high risk lesion, wherein the diagnostic score is based on comparisons between the expression levels of the biomarker miRNAs to the expression level of at least one other biomarker miRNA.

### Claim at position 2

-14. (canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein the pancreas sample is a cystic fluid sample.

### Claim 16 (depends on 15)

The method of claim 15, wherein the sample is obtained by fine needle aspirate.

### Claim at position 5

-23. (canceled)

### Claim 24 (depends on 16)

The method of claim 16, further comprising determining diffpair values after measuring and comparing the level of expression of miRNAs, where the diff pair values are calculated from at least two of the following diffpairs: miR-24/miR-30a-3p; miR-18a/miR-92a; miR-24/miR-342-3p; miR-24/miR-99b; miR-106b/miR-92a; miR-142-3p/miR-92a; or miR-30a-3p/miR-532-3p.

### Claim at position 7

-29. (canceled)

### Claim 30 (depends on 24)

The method of claim 24, further comprising measuring the level of expression of at least one of the following miRNAs: miR-15a, miR-16, miR-21, miR-17-5p, miR-100, miR-107, miR-155, miR-181a, miR-181c, miR-210, miR-221, or miR-223.

### Claim at position 9

-32. (canceled)

### Claim 33 (depends on 1)

The method of claim 1, wherein the diagnostic score is based on determined diff pair values.

### Claim at position 11

-36. (canceled)

### Claim 37 (depends on 1)

The method of claim 1, further comprising resecting all or part of a pancreatic cyst determined to be a high risk lesion.

### Claim at position 13

-45. (canceled)

### Claim 46

A method of evaluating a pancreatic cyst from a patient comprising:
a) from a sample of the pancreatic cyst, measuring the level of expression of at least miR-24 and at least one of the following comparative microRNAs: miR-30a-3p, miR-342-3p, and miR-99b;
b) comparing the level of expression between miR-24 and the at least one comparative microRNA to determine a mitt-24 diffpair value; and,
c) calculating a diagnostic score that indicates whether the pancreatic cyst is a low risk or high risk lesion.

### Claim at position 15

-51. (canceled)

### Claim 52 (depends on 46)

The method of claim 46, wherein the sample is a cystic fluid sample.

### Claim 53 (depends on 46)

The method of claim 46, wherein the cystic fluid sample is obtained by fine needle aspirate.

### Claim 54 (depends on 46)

The method of claim 46, further comprising measuring the sample the level of expression of at least one of the following additional microRNAs: miR-18a, miR-30a-3p, miR-92a, miR-99b, miR-106b, miR-142-3p, miR-342-3p, or miR-532-3p.

### Claim at position 19

-61. (canceled)

### Claim 62 (depends on 46)

The method of claim 46, further comprising determining diffpair values after measuring and comparing the level of expression of miRNAs from at least two of the following diffpairs: miR-24/miR-30a-3p; miR-18a/miR-92a; miR-24/miR-342-3p; miR-24/miR-99b; miR-106b/miR-92a; 42-3p/miR-92a; or miR-30a-3p/miR-532-3p.

### Claim at position 21

-67. (canceled)

### Claim 68 (depends on 46)

The method of claim 46, further comprising measuring the level of expression of at least one of the following miRNAs: miR-15a, miR-16, miR-21, miR017-5p, miR100, miR-107, miR-155, miR-181a, miR-181c, miR-210, miR-221, or miR-223.

### Claim at position 23

-73. (canceled)

### Claim 74 (depends on 46)

The method of claim 46, further comprising determining a treatment for the patient based on a calculated diagnostic score.

### Claim 75 (depends on 46)

The method of claim 46, further comprising resecting all or part of the high risk lesion.

### Claim at position 26

-92. (canceled)

### Claim 93

A method for analyzing a pancreatic cyst sample from a patient comprising:
a) measuring the level of expression in the cyst sample at least two of the following biomarker miRNAs: miR-18a, miR-24, miR-30a-3p, miR-92a, miR-99b, miR-106b, miR-142-3p, miR-342-3p, miR-532-3p;
b) measuring the level of expression of at least one comparative miRNA, wherein the level of expression of the comparative miRNA is compared with one or more biomarker miRNA expression levels;
c) comparing each of the at least two levels ofbiomarker expression with the level of expression of the at least one comparative RNA to determine a diff pair value; and,
d) determining a diagnostic score that indicates the risk for a high risk lesion or a low risk lesion.

### Claim at position 28

-119. (canceled)

### Claim 120

A method for evaluating a pancreatic cyst in a patient comprising:
a) measuring from a pancreatic cyst sample from the patient the level of expression of at least one of the following miRNAs: miR-18a, miR-24, miR-30a-3p, miR-92a, miR-99b, miR-106b, miR-142-3p, miR-342-3p, or miR-532-3p;
b) comparing the level of expression of the at least one miRNA to the level of expression of at least a first comparative microRNA; and,
c) evaluating the sample based on the comparison between the level of expression of the at least one miRNA to the level of expression of at least a first comparative microRNA, wherein the evaluation indicates whether the pancreatic cyst is a low risk or high risk lesion.

### Claim at position 30

-129. (canceled)

### Claim 130

A tangible computer-readable medium comprising computer-readable code that, when executed by a computer, causes the computer to perform operations comprising:
a) receiving information corresponding to a level of expression in a pancreatic cyst sample from a patient of at least two of the following diffpair miRNAs: miR-18a, miR-24, miR-30a-3p, milt-92a, miR-99b, miR-106b, miR-142-3p, miR-342-3p, or miR-532-3p, wherein at least one of the miRNAs is a biomarker miRNA; and
b) determining a biomarker diff pair value using information corresponding to the at least one biomarker miRNA and information corresponding to the level of expression of a comparative micro RNA, the diff pair value being indicative of whether the pancreatic cyst is a low risk or high risk lesion.

### Claim at position 32

-135. (canceled)
